Akoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented a mixed outlook. Positive aspects include significant revenue growth, improved gross margins, and reduced operating losses. However, the lack of shareholder return plans, workforce reductions, and competitive pressures weigh negatively. The Q&A revealed cautious guidance and unresolved questions about cash burn and restructuring impact. The company's focus on achieving cash flow break-even by 2024, without immediate shareholder returns, suggests a cautious market reaction. Given the absence of market cap data, a neutral sentiment is prudent, reflecting balanced positive and negative factors.
Key Financial Performance
Total Revenue $23.2 million, a 26.2% sequential increase from $18.4 million in the first quarter, stable year-over-year performance.
Instrument Revenue $8.3 million, a 70.4% sequential increase from the first quarter, with 51 instruments placed compared to 30 in the first quarter.
Reagent Revenue $7.4 million, a 27.0% year-over-year increase from $5.8 million, and a 5.6% sequential increase from $7.0 million in the first quarter.
Service and Other Revenue $7.2 million, a 16.6% sequential growth from $6.2 million in the first quarter, and a 13.6% year-over-year growth from $6.4 million.
Gross Profit $13.4 million, a 59.8% sequential increase from $8.4 million, and a 10.5% year-over-year increase from $12.1 million.
Gross Margin 57.8%, compared to 45.7% in the first quarter and 51.5% in the prior year period.
Operating Expenses $24.5 million, an 18.3% sequential decrease from $30.0 million in the first quarter, and a 22% year-over-year decrease from $31.4 million.
Loss from Operations $11.1 million, a 48.6% sequential decrease from $21.6 million in the first quarter, and a 42.4% year-over-year decrease from $19.2 million.
Cash and Cash Equivalents Approximately $48.7 million as of June 30, 2024.
Operating Highlights
PhenoCycler Fusion (PCF): The PCF is the top selling spatial proteomics platform with 236 units in the field, supporting high plex tissue analysis.
PhenoImager HT (HT): The HT is the only clinical grade spatial platform with 368 units in the field, used in biopharma clinical trials.
NMPA Approval in China: The HT instrument received NMPA approval in China, allowing integration into clinical workflows across hospitals.
Partnership with NeraCare: An exclusive partnership with NeraCare aims to enable personalized therapy selection for early-stage melanoma.
Manufacturing Center of Excellence: The new center in Marlborough, Massachusetts is fully operational, enhancing reagent development and manufacturing capabilities.
Workforce Reduction: A workforce reduction of approximately 35% was implemented to streamline operations.
Operating Efficiency Goals: Aiming for operating cash flow break-even by the end of 2024.
Revenue Outlook Update: Updated revenue outlook for 2024 is projected between $96 million to $104 million.
Risk or Challenges
Workforce Reduction: Implemented a workforce reduction of approximately 35% compared to end of year 2023, which may impact employee morale and operational capacity.
Regulatory Approval: The PhenoImager HT is on a potential path to achieve U.S. regulatory approval, which carries risks associated with regulatory compliance and potential delays.
Market Competition: Facing competitive pressures in the spatial biology market, particularly from other providers of clinical-grade spatial platforms.
Economic Factors: The company is navigating market conditions that could affect revenue projections and overall financial performance.
Operational Efficiency: The goal of achieving operating cash flow break-even by the end of the year may be challenged by ongoing operational optimization efforts.
Supply Chain Challenges: Earlier reagent availability challenges were noted, although resolved, they highlight potential vulnerabilities in the supply chain.
Guidance & Outlook
Manufacturing Center of Excellence: The new Manufacturing Center of Excellence in Marlborough, Massachusetts, is now fully operational, contributing to a rebound in reagent volumes and instrument placements.
Workforce Reduction: A workforce reduction of approximately 35% was implemented to optimize operations and align teams with corporate objectives.
Product Portfolio Development: Focus on expanding the product portfolio, particularly in oncology and inflammatory disease, while also exploring neurobiology and preclinical drug development.
Clinical Partnerships: Continued partnerships with biopharma companies to enhance clinical trial capabilities and expand market opportunities.
Revenue Outlook: The updated revenue outlook for the full year 2024 is projected to be in the range of $96 million to $104 million.
Operating Cash Flow: The goal is to achieve operating cash flow break-even by the end of 2024.
Gross Margin Improvement: Expectations to improve gross margins through increased reagent revenue mix and operational optimization.
Loss from Operations: Aiming to reduce loss from operations and achieve adjusted EBITDA positivity by the end of 2024.
Shareholder Return Plan
Shareholder Return Plan: Akoya Biosciences has not announced any specific share buyback or dividend program during the call. The focus remains on operational efficiency and achieving cash flow break-even by the end of 2024.
Key Q&A
Earnings Word Cloud
AKYA Transcript
The earnings call summary reveals several negative indicators: a reduced revenue outlook, continued customer spending pressure, and regulatory delays. Despite some operational improvements, financial metrics show significant declines in revenue and instrument sales. The Q&A section highlights concerns over cash flow, strategic uncertainties, and competitive pressures. Although there are some positive aspects, such as gross margin improvements and a focus on shareholder value, the overall sentiment leans negative due to the challenging market environment and financial constraints.
The earnings call presented a mixed outlook. Positive aspects include significant revenue growth, improved gross margins, and reduced operating losses. However, the lack of shareholder return plans, workforce reductions, and competitive pressures weigh negatively. The Q&A revealed cautious guidance and unresolved questions about cash burn and restructuring impact. The company's focus on achieving cash flow break-even by 2024, without immediate shareholder returns, suggests a cautious market reaction. Given the absence of market cap data, a neutral sentiment is prudent, reflecting balanced positive and negative factors.
The earnings call reveals strong financial performance with record revenue growth and optimistic guidance for future margin improvements. The Q&A section highlights strategic partnerships and expected growth in reagents, supporting an optimistic outlook. Despite some macroeconomic pressures, the company's strategic focus on less impacted areas and new product developments bolster confidence. The projected breakeven in operating cash flow further enhances the positive sentiment. However, lack of detailed guidance in some areas tempers expectations slightly, leading to a positive but not strong positive rating.
The earnings call summary indicates strong financial performance with 34% revenue growth, improved gross margins, and effective cost management. Despite competitive pressures and regulatory risks, the company is expanding its product offerings and market reach. The Q&A session revealed positive sentiment, with management addressing concerns and providing optimistic guidance. Although RNA chemistry capabilities are delayed, the overall outlook remains strong, with expectations for further growth and margin improvements. The lack of explicit 2024 guidance is mitigated by thematic insights, maintaining a positive sentiment.
AKYA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
